Enveric Biosciences, Inc.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

ENVB$1.42+1.7%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Item 1. Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024

ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2025	December 31, 2024
(Unaudited)
ASSETS
Current assets:
Cash	$3,757,594	$2,241,026
Prepaid expenses and other current assets	407,946	493,558
Total current assets	4,165,540	2,734,584
Other assets:
Property and equipment, net	196,521	305,777
Intangible assets, net	—	42,182
Total other assets	196,521	347,959
Total assets	$4,362,061	$3,082,543
LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$683,707	$521,747
Due to related parties	—	232,891
Accrued expenses and other current liabilities	222,178	735,098
Total current liabilities	905,885	1,489,736
Commitments and contingencies (Note 9)	-
Mezzanine equity
Series C redeemable preferred stock, $0.01 par value, 100,000 shares authorized, and 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	—	—
Total mezzanine equity	—	—
Shareholders’ equity
Preferred stock, $0.01 par value, 20,000,000 shares authorized; Series B preferred stock, $0.01 par value, 3,600,000 shares authorized, 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	—	—
Common Stock, $0.01 par value, 100,000,000 shares authorized, 518,296 and 56,501 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	5,183	565
Additional paid-in capital	116,684,259	108,261,264
Accumulated deficit	(112,652,321)	(106,074,505)
Accumulated other comprehensive loss	(580,945)	(594,517)
Total shareholders’ equity	3,456,176	1,592,807
Total liabilities, mezzanine equity, and shareholders’ equity	$4,362,061	$3,082,543

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,
	2025	2024	2025	2024
Operating expenses
General and administrative	$1,431,157	$1,195,661	$4,010,313	$4,329,565
Research and development	402,417	802,717	2,408,839	1,873,873
Depreciation and amortization	40,369	84,814	161,373	255,002
Total operating expenses	1,873,943	2,083,192	6,580,525	6,458,440
Loss from operations	(1,873,943)	(2,083,192)	(6,580,525)	(6,458,440)
Other income (expense)
Other (expense) income	—	(623)	2,565	39,386
Interest income (expense), net	274	(217)	144	444
Total other income (expense)	274	(840)	2,709	39,830
Net loss before income taxes	$(1,873,669)	$(2,084,032)	$(6,577,816)	$(6,418,610)
Income tax expense	—	—	—	(1,731)
Net loss	(1,873,669)	(2,084,032)	(6,577,816)	(6,420,341)
Less deemed dividend on inducement of warrants	1,513,449	—	1,513,449	—
Net loss attributable to shareholders	(3,387,118)	(2,084,032)	(8,091,265)	(6,420,341)
Other comprehensive loss
Foreign currency translation	(7,414)	31,497	13,572	34,751
Comprehensive loss	$(3,394,532)	$(2,052,535)	$(8,077,693)	$(6,385,590)
Net loss per share - basic and diluted	$(10.81)	$(43.10)	$(35.74)	$(170.67)
Weighted average shares outstanding, basic and diluted	313,242	48,350	226,400	37,618

See the accompanying notes to the unaudited condensed consolidated financial statements.* *

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY****

	Common Stock
Shares · Amount · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Loss · Total Shareholders’Equity
Balance at January 1, 2025	56,501	$565	$108,261,264	-	$(106,074,505)	$(594,517)	$1,592,807
Issuance of Common Stock and Series A and B and prefunded warrants for cash, net of offering costs of $755,487	102,444	1,024	4,243,443		—	—	4,244,467
Issuance of common shares for vested RSAs	1,215	12	(12)		—	—	—
Issuance of common shares for exercise of warrants	38,528	385	74,659		—	—	75,044
Issuance of round up shares	7,283	73	(73)		—	—	—
Stock based compensation	—	—	193,848		—	—	193,848
Foreign exchange translation loss	—	—	—		—	(3,487)	(3,487)
Net loss	—	—	—	-	(2,184,966)	—	(2,184,966)
Balance at March 31, 2025	205,971	2,059	112,773,129	-	(108,259,471)	(598,004)	$3,917,713
Issuance of common shares for cash pursuant to ATM Agreement, net of offering costs of $179,714	46,197	462	555,042		—	—	555,504
Stock based compensation	—	—	206,260		—	—	206,260
Foreign exchange translation gain	—	—	—		—	24,473	24,473
Net loss	—	—	—	-	(2,519,181)	—	(2,519,181)
Balance at June 30, 2025	252,168	2,521	113,534,431	-	(110,778,652)	(573,531)	$2,184,769
Issuance of common shares for cash pursuant to ATM Agreement, net of offering costs of $37,365	64,045	641	1,080,654		—	—	1,081,295
Exercise of Series A and B Warrants for common shares, net of offering costs of $424,659	202,083	2,021	1,882,193		—	—	1,884,214
Deemed dividend on inducement of warrants of $1,513,449	—	—	—		—	—	—
Stock based compensation	—	—	186,981		—	—	186,981
Foreign exchange translation loss	—	—	—		—	(7,414)	(7,414)
Net loss	—	—	—	-	(1,873,669)	—	(1,873,669)
Balance at September 30, 2025	518,296	$5,183	$116,684,259	-	$(112,652,321)	$(580,945)	$3,456,176

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

	Common Stock
	Shares	Amount	Additional Paid-In Capital	Subscription Receivable	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total Shareholders’ Equity
Balance at January 1, 2024	15,219	$152	$100,843,091	$(1,817,640)	$(96,499,518)	$(569,749)	$1,956,336
Common Stock sold under the Equity Distribution Agreement, net of offering costs of $583,713	9,267	93	1,808,696	—	—	—	1,808,789
Issuance of direct offering shares	1,271	13	322,440	—	—	—	322,453
Exercise of Inducement Warrants for Common Stock	10,856	109	2,676,871	—	—	—	2,676,980
Proceeds from the subscription receivable related to the issuance of Inducement Warrants, net of offering costs of $12,821	—	—	(12,821)	280,500	—	—	267,679
Proceeds from the subscription receivable related to the exercise of warrants and preferred investment options and issuance of Common Stock in abeyance	3,912	39	(39)	1,537,140	—	—	1,537,140
Stock based compensation	—	—	351,488	—	—	—	351,488
Foreign exchange translation gain	—	—	—	—	—	17,906	17,906
Net loss	—	—	—	—	(2,456,915)	—	(2,456,915)
Balance at March 31, 2024	40,525	406	105,989,726	—	(98,956,433)	(551,843)	6,481,856
Stock-based compensation	—	—	369,614	—	—	—	369,614
Common Stock sold under the Purchase Agreement, net of offering costs of $82,850	695	7	(7)	—	—	—	—
Issuance of direct offering shares	2,545	25	448,815	—	—	—	448,840
Issuance of common shares for vested RSU	9	—	—	—	—	—	—
Foreign exchange translation loss	—	—	—	—	—	(14,652)	(14,652)
Net loss	—	—	—	—	(1,879,394)	—	(1,879,394)
Balance at June 30, 2024	43,774	438	106,808,148	—	(100,835,827)	(566,495)	5,406,264
Stock-based compensation	—	—	369,614	—	—	—	369,614
Common Stock sold under the Purchase Agreement, net of offering costs of $290,029	6,059	61	227,746	—	—	—	227,807
Issuance of common shares for vested RSU	144	1	(1)	—	—	—	—
Foreign exchange translation gain	—	—	—	—	—	31,497	31,497
Net loss	—	—	—	—	(2,084,032)	—	(2,084,032)
Balance at September 30, 2024	49,977	$500	$107,405,507	$—	$(102,919,859)	$(534,998)	$3,951,150

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.